A. Saoudi, Prenatal exposure to lead in France: Cord-blood levels and 740 associated factors: Results from the perinatal component of the French Longitudinal 741 Study since Childhood (Elfe), International Journal of Hygiene and Environmental 742 Health, vol.221, issue.3, pp.441-450, 2018.

C. Philippat, Exposure to Phthalates and Phenols during Pregnancy and 744

, Offspring Size at Birth. Environmental Health Perspectives, vol.120, pp.464-470, 2012.

S. G. Howard, Developmental Exposure to Endocrine Disrupting Chemicals and Type 746

, Diabetes Mellitus. Frontiers in endocrinology, vol.9, pp.513-513, 2018.

J. J. Heindel, Developmental Origins of Health and Disease: Integrating 748 Environmental Influences, Endocrinology, vol.156, issue.10, pp.3416-3421, 2015.

J. Sturza, Prenatal exposure to multiple pesticides is associated with auditory 750 brainstem response at 9months in a cohort study of Chinese infants. Environment 751 International, pp.478-485, 2016.

L. L. Aylward, Relationships of chemical concentrations in maternal and cord 753 blood: a review of available data, Journal of Toxicology and Environmental Health, vol.754, issue.17, pp.175-203, 2014.

M. A. Andrew, M. F. Hebert, and P. Vicini, Physiologically based pharmacokinetic 756 model of midazolam disposition during pregnancy, 30th Annual International 757 Conference of the IEEE Engineering in Medicine and Biology Society, 2008.

R. Beaudouin, S. Micallef, and C. Brochot, A stochastic whole-body physiologically 759 based pharmacokinetic model to assess the impact of inter-individual variability on 760 tissue dosimetry over the human lifespan, Regulatory Toxicology and Pharmacology, vol.57, issue.1, pp.103-116, 2010.

K. Abduljalil, Anatomical, Physiological and Metabolic Changes with 763 Gestational Age during Normal Pregnancy, Clinical Pharmacokinetics, vol.51, issue.6, pp.764-365, 2012.

A. Dallmann, Gestation-Specific Changes in the Anatomy and Physiology of 766 Healthy Pregnant Women: An Extended Repository of Model Parameters for 767 Physiologically Based Pharmacokinetic Modeling in Pregnancy, Clinical, vol.768, issue.11, pp.1303-1330, 2017.

A. B. Ke, A physiologically based pharmacokinetic model to predict disposition 770 of CYP2D6 and CYP1A2 metabolized drugs in pregnant women. Drug metabolism and 771 disposition: the biological fate of chemicals, vol.41, p.12, 2013.

V. K. Jogiraju, Application of physiologically based pharmacokinetic modeling 773 to predict drug disposition in pregnant populations. Biopharmaceutics & Drug 774 Disposition, vol.38, pp.426-438, 2017.

R. A. Corley, Evaluation of Physiologically Based Models of Pregnancy and 776 Lactation for Their Application in Children's Health Risk Assessments, Critical Reviews, vol.777, issue.2, pp.137-211, 2003.

P. Myllynen and K. Vähäkangas, Placental transfer and metabolism: An overview of 779 the experimental models utilizing human placental tissue, Toxicology in Vitro, vol.27, issue.780, pp.507-512, 2013.

G. J. Burton and E. Jauniaux, What is the placenta?, American Journal of Obstetrics & 782 Gynecology, vol.213, issue.4, p.16, 2015.

M. Myren, The human placenta -An alternative for studying foetal exposure. 784 Toxicology in Vitro, vol.21, pp.1332-1340, 2007.

N. M. Gude, Growth and function of the normal human placenta, vol.114, pp.397-407, 2004.

D. Beghin, Le passage placentaire des médicaments. Revue de médecine périnatale, vol.6, pp.12-20, 2014.

M. Rothbauer, A comparative study of five physiological key parameters between 790 four different human trophoblast-derived cell lines, Endocrine Regulation of Feto-Placental Growth, vol.7, issue.1, pp.791-5892, 2017.

, Hormone Research in Paediatrics, vol.72, issue.5, pp.257-265, 2009.

C. Giaginis, S. Theocharis, and A. Tsantili-kakoulidou, Current toxicological aspects 795 on drug and chemical transport and metabolism across the human placental barrier

, Expert Opinion on Drug Metabolism & Toxicology, vol.8, issue.10, p.22, 2012.

S. K. Griffiths and J. P. Campbell, Placental structure, function and drug transfer

, Continuing Education in Anaesthesia Critical Care & Pain, vol.15, p.23, 2015.

B. Huppertz, The anatomy of the normal placenta, Journal of Clinical Pathology, vol.800, issue.12, p.24, 2008.

R. M. Lewis, The Placental Exposome: Placental Determinants of Fetal Adiposity 802 and Postnatal Body Composition, Annals of Nutrition and Metabolism, vol.63, issue.3, p.25, 2013.

W. Aherne and M. S. Dunnill, Morphometry of the human placent, British Medical 805 Bulletin, vol.22, issue.1, pp.5-8, 1966.

G. J. Burton, Uterine Glands Provide Histiotrophic Nutrition for the Human Fetus 807 during the First Trimester of Pregnancy, The Journal of Clinical Endocrinology & 808 Metabolism, vol.87, issue.6, pp.2954-2959, 2002.

B. V. Sastry, Techniques to study human placental transport, vol.38, pp.17-39, 1999.

Z. Shu-feng, Placental Drug Disposition and Its Clinical Implications. Current 812 Drug Metabolism, vol.9, p.29, 2008.

M. R. Syme, J. W. Paxton, and J. A. Keelan, Drug Transfer and Metabolism by the 814 Human Placenta, Clinical Pharmacokinetics, vol.43, issue.8, p.89, 2004.

A. Dallmann, Physiologically Based Pharmacokinetic Modeling of Renally 991 Cleared Drugs in Pregnant Women, Clinical Pharmacokinetics, vol.56, issue.12, p.90, 2017.

A. A. Geraghty, Maternal and fetal blood lipid concentrations during pregnancy 994 differ by maternal body mass index: findings from the ROLO study. BMC pregnancy 995 and childbirth, vol.17, pp.360-360, 2017.

H. J. Clewell, Evaluation of the Uncertainty in an Oral Reference Dose for 997

, Methylmercury Due to Interindividual Variability in Pharmacokinetics. Risk Analysis, vol.998, pp.547-558, 1999.

W. Schmitt, General approach for the calculation of tissue to plasma partition 1000 coefficients, Toxicology in Vitro, vol.22, issue.2, p.93, 2008.

P. Poulin, K. Schoenlein, and F. P. Theil, Prediction of adipose tissue: Plasma partition 1002 coefficients for structurally unrelated drugs, Journal of Pharmaceutical Sciences, vol.90, issue.4, pp.436-447, 1003.

P. Poulin and F. P. Theil, A Priori Prediction of Tissue:Plasma Partition Coefficients 1005 of Drugs to Facilitate the Use of Physiologically‐Based Pharmacokinetic 1006 Models in Drug Discovery, Journal of Pharmaceutical Sciences, vol.89, issue.1, p.95, 2000.

C. Giaginis, Application of quantitative structure-activity relationships for 1008 modeling drug and chemical transport across the human placenta barrier: a 1009 multivariate data analysis approach, Journal of Applied Toxicology, vol.29, issue.8, p.96, 2009.

M. Hewitt, Structure-based modelling in reproductive toxicology: (Q)SARs for 1012 the placental barrier. SAR and QSAR in Environmental Research, vol.18, p.97, 2007.

F. Lu, Prediction of placenta barrier permeability and reproductive toxicity of 1015 compounds in tocolytic Chinese herbs using support vector machine, International 1016 Conference on Materials Engineering and Information Technology Applications, p.1017, 2015.

Y. Zhang, Prediction of Placental Barrier Permeability: A Model Based on 1019

, Partial Least Squares Variable Selection Procedure. Molecules, vol.20, p.99, 2015.

A. Eguchi, Maternal-fetal transfer rates of PCBs, OCPs, PBDEs, and dioxin-1022 like compounds predicted through quantitative structure-activity relationship 1023 modeling, Environmental Science and Pollution Research, vol.25, issue.8, pp.7212-7222, 2018.

T. Takaku, Quantitative Structure-Activity Relationship Model for the Fetal-1025 Maternal Blood Concentration Ratio of Chemicals in Humans. Biological and 1026 Pharmaceutical Bulletin, vol.38, pp.930-934, 2015.

M. and A. Golan, In Vitro Models Using the Human Placenta to Study Fetal 1028 Exposure to Drugs. Clinical medicine. Reproductive health, vol.2, pp.15-24, 2008.

D. A. Evseenko, J. W. Paxton, and J. A. Keelan, ABC drug transporter expression and 1030 functional activity in trophoblast-like cell lines and differentiating primary trophoblast

, American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, vol.290, issue.5, pp.1357-1365, 1032.

F. Liu, M. J. Scares, and K. L. Audus, Permeability and biochemical properties of BeWo 1034 trophoblast cell monolayers, Placenta, vol.17, issue.5, p.25, 1996.

H. Li, Assessment of an in vitro transport model using BeWo b30 cells to predict 1036 placental transfer of compounds, Archives of Toxicology, vol.87, issue.9, pp.1661-1669, 2013.

M. S. Poulsen, Modeling placental transport: Correlation of in vitro BeWo cell 1038 permeability and ex vivo human placental perfusion, Toxicology in Vitro, vol.23, issue.7, pp.1039-1380, 2009.

L. Aengenheister, An advanced human in vitro co-culture model for translocation 1041 studies across the placental barrier, Scientific Reports, vol.8, issue.1, p.5388, 2018.

J. Lee, Placenta-on-a-chip: a novel platform to study the biology of the human 1043 placenta, The Journal of Maternal-Fetal & Neonatal Medicine, vol.29, issue.7, p.1054, 2016.

C. Blundell, A microphysiological model of the human placental barrier. Lab on 1046 a chip, vol.16, pp.3065-3073, 2016.

F. Yin, A 3D human placenta-on-a-chip model to probe nanoparticle exposure 1048 at the placental barrier, Toxicology in Vitro, vol.54, pp.105-113, 2019.

X. Huang, Establishment of a confluent monolayer model with human primary 1050 trophoblast cells: novel insights into placental glucose transport. MHR: Basic science 1051 of reproductive medicine, vol.22, pp.442-456, 2016.

S. Kallol, Novel Insights into Concepts and Directionality of Maternal-Fetal 1053

, Cholesterol Transfer across the Human Placenta, International Journal of Molecular 1054 Sciences, issue.8, p.19, 2018.

Z. Zhang and J. D. Unadkat, Verification of a Maternal-Fetal Physiologically Based 1056

, Pharmacokinetic Model for Passive Placental Permeability Drugs. Drug Metabolism 1057 and Disposition, pp.116-073957, 2017.

D. R. Varma and R. Ramakrishnan, A rat model for the study of transplacental 1059 pharmacokinetics and its assessment with antipyrine and aminoisobutyric acid, Journal 1060 of Pharmacological Methods, vol.14, issue.1, pp.61-74, 1985.

J. Kanto, Placental transfer and maternal midazolam kinetics, Clinical 1062 Pharmacology & Therapeutics, vol.33, pp.786-791, 1983.

, Placental perfusion experiments, American Journal of Obstetrics and 1064 Gynecology, vol.84, issue.11, pp.1664-1683, 1962.

R. K. Miller, Human Placenta in vitro: Characterization during 12 h of Dual 1066

, In vitro Perfusion of Human Placental Tissue, H. Schneider and J. Dancis, 1067 Editors, pp.77-84, 1985.

H. Schneider, Evaluation of an In Vitro Dual Perfusion System for the Study of 1069 Placental Proteins: Energy Metabolism

A. Genba?ev, R. Klopper, and . Beaconsfield, , pp.39-50, 1071.

T. I. Ala-kokko, P. Myllynen, and K. Vähäkangas, Ex vivo perfusion of the human 1073 placental cotyledon: implications for anesthetic pharmacology, International Journal of 1074 Obstetric Anesthesia, vol.9, issue.1, pp.26-38, 2000.

J. R. Hutson, The Human Placental Perfusion Model: A Systematic Review and 1076 Development of a Model to Predict In Vivo Transfer of Therapeutic Drugs, Clinical 1077 Pharmacology & Therapeutics, vol.90, issue.1, pp.67-76, 2011.

T. Heikkinen, U. Ekblad, and K. Laine, Transplacental transfer of citalopram, 1079 fluoxetine and their primary demethylated metabolites in isolated perfused human 1080 placenta, BJOG: An International Journal of Obstetrics & Gynaecology, vol.109, issue.9, pp.1081-1003, 2002.

J. M. Julius, Evaluation of the maternal-fetal transfer of granisetron in an ex vivo 1083 placenta perfusion model, Reproductive Toxicology, vol.49, pp.43-47, 2014.

C. Jovelet, Variation in transplacental transfer of tyrosine kinase inhibitors in 1085 the human perfused cotyledon model, Annals of Oncology, vol.26, issue.7, pp.1500-1504, 2015.

C. Vinot, Bidirectional Transfer of Raltegravir in an Ex Vivo Human Cotyledon 1087

, Perfusion Model. Antimicrobial agents and chemotherapy, vol.60, issue.5, pp.3112-3114, 2016.

L. Mandelbrot, Placental transfer of rilpivirine in an ex vivo human cotyledon 1089 perfusion model, Antimicrobial agents and chemotherapy, vol.59, issue.5, pp.2901-2903, 2015.

J. J. Freriksen, Placental disposition of the immunosuppressive drug tacrolimus 1091 in renal transplant recipients and in ex vivo perfused placental tissue, European Journal 1092 of Pharmaceutical Sciences, vol.119, pp.244-248, 2018.

K. Shintaku, Prediction and evaluation of fetal toxicity induced by NSAIDs using 1094 transplacental kinetic parameters obtained from human placental perfusion studies. 1095 British journal of clinical pharmacology, vol.73, pp.248-256, 2012.

S. Schalkwijk, Prediction of Fetal Darunavir Exposure by Integrating Human 1097

. Ex-vivo, Placental Transfer and Physiologically Based Pharmacokinetic Modeling, Clinical pharmacokinetics, vol.57, issue.6, pp.705-716, 1098.

J. W. Fisher, Physiologically based pharmacokinetic modeling of the pregnant 1100 rat: A multiroute exposure model for trichloroethylene and its metabolite, 1101 trichloroacetic acid, Toxicology and Applied Pharmacology, vol.99, issue.3, pp.395-414, 1989.

C. Emond, A physiologically based pharmacokinetic model for developmental 1103 exposure to BDE-47 in rats, Toxicology and Applied Pharmacology, vol.242, issue.3, pp.1104-290, 2010.

C. Emond, An assessment of dioxin exposure across gestation and lactation using 1106 a PBPK model and new data from Seveso. Environment international, pp.1107-1130, 2016.

L. W. Han, C. Gao, and Q. Mao, An update on expression and function of P-gp/ABCB1 1109 and BCRP/ABCG2 in the placenta and fetus. Expert Opinion on Drug Metabolism & 1110 Toxicology, vol.14, pp.817-829, 2018.

J. C. Challier, La barrière placentaire : structure, résistance, asymétrie. Reproduction 1112 Nutrition Development, vol.29, pp.703-716, 1989.

M. Dahl-andersen, Animal Models of Fetal Medicine and Obstetrics, in 1114 Experimental Animal Models of Human Diseases -An Effective Therapeutic Strategy, 1115.

D. Hirt, Pharmacokinetic modelling of the placental transfer of nelfinavir and its 1117 M8 metabolite: a population study using 75 maternal-cord plasma samples, British 1118 Journal of Clinical Pharmacology, vol.64, issue.5, pp.634-644, 2007.

G. D. Shapiro, Exposure to organophosphorus and organochlorine pesticides, 1120 perfluoroalkyl substances, and polychlorinated biphenyls in pregnancy and the 1121 association with impaired glucose tolerance and gestational diabetes mellitus: The 1122 MIREC Study, Environmental Research, vol.147, pp.71-81, 2016.

S. Lignell, Maternal body burdens of PCDD/Fs and PBDEs are associated with 1124 maternal serum levels of thyroid hormones in early pregnancy: a cross-sectional study. 1125 Environmental health, vol.15, pp.55-55, 2016.

S. S. Andra, C. Austin, and M. Arora, Tooth matrix analysis for biomonitoring of 1127 organic chemical exposure: Current status, challenges, and opportunities. 1128 Environmental research, vol.142, pp.387-406, 2015.

A. M. Tsatsakis, Dialkyl phosphates in meconium as a biomarker of prenatal 1130 exposure to organophosphate pesticides: A study on pregnant women of rural areas in 1131

G. Crete and . Xenobiotica, , vol.39, pp.364-373, 2009.

D. Koutroulakis, Dialkyl phosphates in amniotic fluid as a biomarker of fetal 1133 exposure to organophosphates in Crete, Greece; association with fetal growth. 1134 Reproductive Toxicology, vol.46, pp.98-105, 2014.

Y. Wan, Hydroxylated Polybrominated Diphenyl Ethers and Bisphenol A in 1136 Pregnant Women and Their Matching Fetuses: Placental Transfer and Potential Risks. 1137 Environmental Science & Technology, vol.44, pp.5233-5239, 2010.

X. Cao, Bisphenol A in human placental and fetal liver tissues collected from 1139

, Greater Montreal area (Quebec) during, Chemosphere, vol.89, issue.5, p.511, 1998.

L. L. Needham, Partition of environmental chemicals between maternal and fetal 1142 blood and tissues. Environmental science & technology, vol.45, pp.1121-1126, 2011.

M. Mandy and M. Nyirenda, Developmental Origins of Health and Disease: the 1144 relevance to developing nations, International health, vol.10, issue.2, pp.66-70, 2018.

D. F. Kapraun, Empirical models for anatomical and physiological changes in a 1146 human mother and fetus during pregnancy and gestation, PloS one, vol.14, issue.5, pp.1147-0215906, 2019.

M. Mölsä, Functional role of P-glycoprotein in the human blood-placental 1149 barrier, Clinical Pharmacology & Therapeutics, vol.78, issue.2, pp.123-131, 2005.

B. E. Gluzman and H. Niepomniszcze, Kinetics of the iodide trapping mechanism in 1151 normal and pathological human thyroid slices, Acta Endocrinologica, vol.103, issue.1, pp.1152-1186, 1983.

J. Wolff and J. R. Walrey, Thyroidal iodide transport: IV. The role of ion size. 1154, Biochimica et Biophysica Acta, vol.69, pp.58-67, 1963.

M. De-sousa-mendes, Prediction of human fetal pharmacokinetics using ex vivo 1156 human placenta perfusion studies and physiologically based models. British journal of 1157 clinical pharmacology, vol.81, pp.646-657, 2016.

A. Ring, Hepatic Maturation of Human Fetal Hepatocytes in Four-Compartment 1159

, Three-Dimensional Perfusion Culture, Tissue Engineering Part C: Methods, vol.16, issue.5, pp.835-845, 1160.

A. Naveed-shaik, S. K. Aleem, and A. Khan, Metabolism of six CYP probe substrates 1162 in fetal hepatocytes, 2016.

N. Bouazza, Methodological Approaches To Evaluate Fetal Drug Exposure, vol.25, pp.1-1, 2019.

S. A. Saghir, S. A. Khan, and A. T. Mccoy, Ontogeny of mammalian metabolizing 1166 enzymes in humans and animals used in toxicological studies, Critical Reviews in, vol.42, issue.5, pp.323-357, 2012.

A. Dallmann, Drug Transporters Expressed in the Human Placenta and Models 1169 for Studying Maternal-Fetal Drug Transfer, The Journal of Clinical Pharmacology, vol.59, issue.S1, pp.70-81, 1170.

P. Berveiller, Drug transporter expression during in vitro differentiation of first-1172 trimester and term human villous trophoblasts, Placenta, vol.36, issue.1, pp.93-96, 2015.

S. M. Bell, In vitro to in vivo extrapolation for high throughput prioritization and 1174 decision making, Toxicology in Vitro, vol.47, pp.213-227, 2018.

O. E. Jensen and I. L. Chernyavsky, Blood Flow and Transport in the Human Placenta

, Annual Review of Fluid Mechanics, vol.51, issue.1, pp.25-47, 2019.

L. Olanoff and J. Anderson, Controlled release of tetracycline-III: A physiological 1178 pharmacokinetic model of the pregnant rat, Journal of Pharmacokinetics and 1179 Biopharmaceutics, vol.8, pp.599-620, 1980.

P. R. Gentry, T. R. Covington, and H. J. Clewell, Evaluation of the potential impact of 1181 pharmacokinetic differences on tissue dosimetry in offspring during pregnancy and 1182 lactation, Regulatory Toxicology and Pharmacology, vol.38, issue.1, pp.1-16, 2003.